Side effects
| Parameters | All | Boceprevir | Telaprevir | p-Value |
|---|---|---|---|---|
| n=23 | n=8 | n=15 | ||
| Fatigue | 20 (87) | 7 (87.5) | 13 (86.7) | 1 |
| Depression | 5 (21.7) | 0 | 5 (33.3) | 0.12 |
| Nausea | 5 (21.7) | 2 (25) | 3 (20) | 1 |
| Skin or subcutaneous tissue disorder | ||||
| Toxic skin eruption | 1 | |||
| Grade 1 | 1 (4.3) | 0 | 1 (6.6) | |
| Grade 2 | 1 (4.3) | 0 | 1 (6.6) | |
| Pruritus | 9 (39.1) | 2 (25) | 7 (46.6) | 0.4 |
| Haematologic variables | ||||
| Decreased haemoglobin concentration | 0.22 | |||
| Grade 1: 9.5–10.9 g/dl | 3 (13) | 1 (12.5) | 2 (13.3) | |
| Grade 2: 8.0–9.4 g/dl | 11 (47.8) | 2 (25) | 9 (60) | |
| Grade 3: 6.5–7.9 g/dl | 3 (13) | 1 (12.5) | 2 (13.3) | |
| Grade 4: <6.5 g/dl | 0 | 0 | 0 | |
| Erythropoietin use | 20 (87) | 7 (87.5) | 13 (86.6) | 1 |
| Red-cell transfusion | 9 (39.1) | 2 (25) | 7 (46.6) | 0.4 |
| Decreased absolute neutrophil count | 0.56 | |||
| Grade 1: 1500–1900/mm3 | 2 (8.7) | 0 | 2 (13.3) | |
| Grade 2: 1000–1400/mm3 | 8 (34.8) | 4 (50) | 4 (26.6) | |
| Grade 3: 500–1000/mm3 | 8 (34.8) | 3 (37.5) | 5 (33.3) | |
| Grade 4: <500/mm3 | 2 (8.7) | 1 (12.5) | 1 (6.6) | |
| Use of granulocyte-stimulating agent | 2 (8.7) | 1 (12.5) | 1 (6.6) | 1 |
| Decreased platelet count | 0.59 | |||
| Grade 1: 75000–99000/mm3 | 3 (13) | 0 | 3 (20) | |
| Grade 2: 50000–74000/mm3 | 8 (34.8) | 3 (37.5) | 5 (33.3) | |
| Grade 3: 25000–49000/mm3 | 4 (17.4) | 1 (12.5) | 3 (20) | |
| Grade 4:<25000/mm3 | 0 | 0 | 0 | |
| Infection | 11 (47.8) | 3 (37.5) | 8 (53.3) | 0.67 |
| Urinary tract | 3 (13) | 2 (25) | 1 (6.6) | |
| Pneumopathy | 3 (13) | 1 (12.5) | 2 (13.3) | |
| Cholecystitis | 1 (4.3) | 0 | 1 (6.6) | |
| Dental abscess | 1 (4.3) | 0 | 1 (6.6) | |
| Breast abscess | 1 (4.3) | 0 | 1 (6.6) | |
| Otitis | 1 (4.3) | 0 | 1 (6.6) | |
| Reason for discontinuation | ||||
| Virological non-response | 5 (21.7) | 3 (37.5) | 2 (13.3) | |
| Virological relapse | 2 (8.7) | 0 | 2 (13.3) | |
| Depression | 1 (4.3) | 1 (12.5) | 0 | |
Except where indicated otherwise values are n (%).